AS601245

发表于由

AS601245  纯度: 98.70%

AS601245 是一种口服活性、选择性、ATP竞争性的 JNK 抑制剂，IC50 分别为 150、220和 70 nM，对三种 JNK 人类亚型 (hJNK1、hJNK2和hJNK3)。AS601245 对 c-src、CDK2 和 c-Raf 的选择性为 10-20 倍，对一系列 Ser/Thr 和 Tyr 蛋白激酶的选择性为 50-100 倍。具有神经保护特性。

AS601245

AS601245 Chemical Structure

CAS No. : 345987-15-7

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥1320 In-stock
5 mg ￥1200 In-stock
10 mg ￥2100 In-stock
50 mg ￥8100 In-stock
100 mg ￥13500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

AS601245 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • MAPK Compound Library
  • Anti-Cancer Compound Library
  • Reprogramming Compound Library
  • Oxygen Sensing Compound Library
  • Orally Active Compound Library
  • Neuroprotective Compound Library
  • Anti-Parkinson’s Disease Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library
  • Targeted Diversity Library

生物活性

AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties[1][2].

IC50 & Target[1]

hJNK1

150 nM (IC50)

hJNK2

220 nM (IC50)

hJNK3

70 nM (IC50)

体外研究
(In Vitro)

AS601245, an anti-Inflammatory JNK inhibitor, and Clofibrate have a synergistic effect in inducing cell responses and in affecting the gene expression profile in CaCo-2 colon cancer cells [2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

AS601245 (40, 60, and 80 mg/kg; i.p.) provides significant protection against the delayed loss of hippocampal CA1 neurons in a gerbil model of transient global ischemia[1].
AS601245 (0.3-10 mg/kg; p.o.) is a potent inhibitor of LPS-induced TNF-α release in mice[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C3H/HEN mice[1]
Dosage: 0.3, 1, 3, or 10 mg/kg
Administration: P.o.
Result: Decreased the TNF-α release in a dose-dependent manner.

分子量

372.45

Formula

C20H16N6S
CAS 号

345987-15-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 10 mg/mL (26.85 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6849 mL 13.4246 mL 26.8492 mL
5 mM 0.5370 mL 2.6849 mL 5.3698 mL
10 mM 0.2685 mL 1.3425 mL 2.6849 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 100% PEG-300

    Solubility: 20 mg/mL (53.70 mM); Suspended solution; Need ultrasonic

  • 2.

    请依序添加每种溶剂： 0.5% MC  0.5% Tween-80

    Solubility: 5 mg/mL (13.42 mM); Suspended solution; Need ultrasonic

  • 3.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1 mg/mL (2.68 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (2.68 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 4.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 1 mg/mL (2.68 mM); Clear solution

    此方案可获得 ≥ 1 mg/mL (2.68 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 10.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Carboni S, et al. AS601245 (1,3-benzothiazol-2-yl (2-[[2-(3-pyridinyl) ethyl] amino]-4 pyrimidinyl) acetonitrile): a c-Jun NH2-terminal protein kinase inhibitor with neuroprotective properties. J Pharmacol Exp Ther. 2004;310(1):25-32.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务